


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (original) Compounds of general formula (I):




(I)


in which

- R₁ is a hydrogen atom or a C₁-C₄ alkyl group;
- R₂ and R₃, which can be the same or different, are a C₁-C₄ alkyl group, or R₂ and R₃, together with the carbon atom which they are linked to, form a cyclic aliphatic group having 3 to 7 carbon atoms or a heterocyclic aliphatic group having 3 to 7 atoms, one or two of which are selected from the group N, O, S and the others being C atoms;
- R₄ and R₅, which can be the same or different, are a hydrogen atom or a C₁-C₄ alkyl group;
- X is selected from the group consisting of halogen, OR₁, SR₁, CN, C₁-C₄ alkyl;
- B has at least one amino group with basic characteristics or a tetraalkylammonium group and can be selected from the group consisting of:


- $\text{NR}_6(\text{CH}_2)_n\text{NHCOY}$, $\text{NR}_6(\text{CH}_2)_n\text{N}(\text{R}_6)-\text{Y}$, $\text{NR}_6(\text{CH}_2)_n\text{N}(\text{Y})_2$, NR_6Y , $\text{N}(\text{Y})_2$, $\text{N}(\text{Y})(\text{CH}_2)_p\text{Y}_1$ and from the residues:



- R_6 is a hydrogen atom, $\text{C}_1\text{-C}_6$ alkyl,
- $n = 1\text{-}12$ and
- Y is selected from: hydrogen, $(\text{CH}_2)_p\text{Y}_1$, $(\text{CH}_2)_p\text{NR}_6\text{Y}_1$, $(\text{CH}_2)_p\text{N}(\text{Y}_1)_2$, NR_5R_6 , $-\text{NR}_6(\text{CH}_2)_q\text{Y}_1$ or from the following residues:



- T is selected from the group of $-\text{NR}_7\text{R}_8$, $-\text{NR}_{14}\text{R}_{18}\text{R}_{19}$, $-\text{OR}_6$;
- R_7 and R_8 , which can be the same or different, are a hydrogen atom, a $\text{C}_1\text{-C}_4$ alkyl group, a cyclohexyl group, or NR_7R_8 together are a group selected from :i) guanidine optionally substituted with 1 or 2 $\text{C}_1\text{-C}_4$ alkyl or cyclohexyl groups, ii) a 5-7 membered nitrogen heterocycle optionally containing another heteroatom selected from O, N, S;
- Y_1 is selected from the group consisting of NR_7R_8 , $\text{NR}_{14}\text{R}_{18}\text{R}_{19}$ or from the following residues:



- Z is selected from the group consisting of H, C₁-C₆ alkyl, OR₆, SR₆, CF₃, OCOR₆, COR₁₀, NHCOR₆, SO₂R₆, SOR₆, CO₂R₆, N(R₆)₂, Cl, Br, NO₂, NH₂, CN, F, imidazole, phenyl, amidine, guanidine, guanidyl-methyl;
- R₉ is selected from the group consisting of hydrogen, - (CH₂)_q-L, wherein L is selected from the group of -OH, -NR₅R₆, -NR₁₄R₁₈R₁₉, amidine optionally substituted with 1 or 2 C₁-C₄ alkyl groups, guanidine optionally substituted with 1 or 2 C₁-C₄ alkyl groups;
- R₁₀ is selected from the group consisting of OR₆, NR₆R₁₂;
- R₁₁ is selected from the group consisting of hydrogen, - (CH₂)_q-L, - (CH₂)_p-NR₄- (CH₂)_q-L;
- R₁₂ is a hydrogen atom, C₁-C₆ alkyl, COR₆,
- R₁₃ is selected from the group consisting of H, C₁-C₆ alkyl, - (CH₂)_pW(CH₂)_qY₁, Y, -COY, -CH₂-Y;
- R₁₅ is selected from the group consisting of hydrogen or straight or branched C₁-C₄ alkyl groups;
- the -NR₁₆R₁₇ group is a 5-7 membered nitrogen aliphatic heterocycle optionally containing another heteroatom selected from O, S, N;
- the -NR₁₄R₁₈R₁₉ group is a quaternary ammonium group in which: R₁₄ is selected from the group consisting of straight or branched C₁-C₄ alkyl groups, R₁₈ and R₁₉, which can be the same or different, are a straight or branched C₁-C₄ alkyl group, or

-NR₁₈R₁₉ is a 5-7 membered nitrogen heterocycle optionally containing another heteroatom selected from O, N, S.

- W = CH₂, O, S, NR₄, N(R₄)₂

- p = 1-6, q = 1-6; and

the pharmacologically acceptable salts thereof with inorganic or organic acids selected from the group of: hydrochloric, hydrobromic, hydroiodic, sulfuric, phosphoric, acetic, trifluoroacetic, propionic, oxalic, malic, maleic, succinic, malonic, aspartic, glutamic acids and possible optical isomers or their mixtures, including the racemates.

2. (original) Compounds as claimed in claim 1, in which


- R₁ is a hydrogen atom or a C₁-C₄ alkyl group;

- R₂ and R₃, which can be the same or different, are a C₁-C₄ alkyl group, or R₂ and R₃, together with the carbon atom which they are linked to, form a cyclic aliphatic group having 3 to 7 carbon atoms or a heterocyclic aliphatic group having 3 to 7 atoms one or two of which are selected from the group of N, O, S and the other being C atoms;


- R₄ and R₅, which can be the same or different, are a hydrogen atom or a C₁-C₄ alkyl group;

- X is selected from the group consisting of halogen, OR₁, SR₁, CN, C₁-C₄ alkyl;


- B has at least one amino group with basic characteristics or a tetraalkylammonium and can be selected from the group consisting of:



- R_6 is a hydrogen atom, C_1 - C_6 alkyl;
- Y is selected from: hydrogen, $(CH_2)_p Y_1$, $(CH_2)_p N R_6 Y_1$, $(CH_2)_p N (Y_1)_2$, $N R_5 R_6$, $- N R_6 (CH_2)_p Y_1$ or from the following residues:




- T is selected from the group of $-N R_7 R_8$, $-N R_{14} R_{18} R_{19}$, $-O R_6$;
- R_7 and R_8 , which can be the same or different, are a hydrogen atom, a C_1 - C_4 alkyl group, or $N R_7 R_8$ is a group selected from: i) guanidine optionally substituted with 1 or 2 C_1 - C_4 alkyl groups, cyclohexyl, ii) a 5-7 membered nitrogen heterocycle optionally containing another heteroatom selected from O, N, S;
- Y_1 is selected from the group consisting of $N R_7 R_8$, $N R_{14} R_{18} R_{19}$ or from the following residues:




- Z is selected from the group consisting of H, C₁-C₆ alkyl, OR₆, SR₆, CF₃, OCOR₆, COR₁₀, NHCOR₆, SO₂R₆, SOR₆, CO₂R₆, N(R₆)₂, C₁, Br, NO₂, NH₂, CN, F, imidazole, phenyl, amidine, guanidine, guanidyl-methyl;
- R₉ is selected from the group consisting of hydrogen, - (CH₂)_q-L, wherein L is selected from the -OH group, -NR₅R₆, -NR₁₄R₁₈R₁₉, amidine optionally substituted with 1 or 2 C₁-C₄ alkyl groups, guanidine optionally substituted with 1 or 2 C₁-C₄ alkyl groups;
- R₁₀ is selected from the group consisting of OR₆, NR₆R₁₂;
- R₁₁ is selected from the group consisting of hydrogen, - (CH₂)_q-L, - (CH₂)_p-NR₄- (CH₂)_q-L;
- R₁₂ is a hydrogen atom, C₁-C₆ alkyl, COR₆;
- R₁₃ is selected from the group consisting of H, C₁-C₆ alkyl, - (CH₂)_pW(CH₂)_qY₁, Y, -COY, -CH₂-Y;
- R₁₄ is selected from the group consisting of straight or branched C₁-C₄ alkyl groups;
- R₁₅ is selected from the group consisting of hydrogen or straight or branched C₁-C₄ alkyl groups;
- the -NR₁₆R₁₇ group is a 5-7 membered nitrogen aliphatic heterocycle optionally containing another heteroatom selected from O, S, N;
- the -NR₁₄R₁₈R₁₉ group is a quaternary ammonium group in which: R₁₄ is selected from the group consisting of straight or branched C₁-C₄ alkyl groups, R₁₈ and R₁₉, which can be the same or different, are a straight or branched C₁-C₄ alkyl group, or -NR₁₈R₁₉ is a 5-7 membered nitrogen heterocycle optionally containing another heteroatom selected from O, N, S;
- W = CH₂, O, S, NR₄, N(R₄)₂;
- p = 1-6, q = 1-6.

3. (currently amended) Compounds as claimed in claim 2, of general formula (I), in which:

- B is selected from the group consisting of the residues:




- **Y** is selected from: $(\text{CH}_2)_p\text{Y}_1$, $(\text{CH}_2)_p\text{NR}_6\text{Y}_1$, $(\text{CH}_2)_p\text{N}(\text{Y}_1)_2$, NR_5R_6 , or from the following residues:




which T is selected from the group of $-NR_7R_8$, $-OR_6$ and the other substituents are as previously defined in claim 2.

4. (currently amended) Compounds as claimed in claim 3, in which:

- R_1 is a hydrogen atom or methyl;
- R_2 and R_3 , which can be the same or different, are selected from methyl or ethyl, or R_2 and R_3 , together with the carbon atom which they are linked to, form a cyclic aliphatic group having 3 to 7 carbon atoms;
- R_4 and R_5 , which can be the same or different, are a hydrogen or a methyl;
- X is a chlorine atom;
- B is a group selected from:




in which R_{13} is H, or a $Y = Y_1$ group in which Y_1 is



- R_{11} is selected from the group consisting of hydrogen, -
 $(CH_2)_q-L$, - $(CH_2)_p-NR_4-(CH_2)_q-L$ wherein L is selected from -OH, -
 NR_5R_6 , amidine optionally substituted with 1 or 2 C_1-C_4 alkyl
groups, guanidine optionally substituted with 1 or 2 C_1-C_4
alkyl groups;
and the other substituents are as previously defined ~~in claim~~
2.


5. (currently amended) Compounds as claimed in claim 3, of
general formula (I) in which:

- R_2 and R_3 , which can be the same or different, are
selected from methyl or ethyl, or R_2 and R_3 , together with the
carbon atom which they are linked to, form a cyclic aliphatic
group having 3 to 7 carbon atoms;
- R_4 and R_5 , which can be the same or different, are a
hydrogen or a methyl,
- X is a chlorine atom;
- B contains at least two amino groups with basic
characteristics, in the free or salified form, and is selected
from the group of:



in which R_{13} is COY , CH_2Y , $-(CH_2)_pW(CH_2)_qY_1$,


- **Y** is a group $(\text{CH}_2)_p\text{Y}_1$, or is selected from:



wherein T is selected from $-NR_7R_8$, $-OR_6$;

- R_7 and R_8 , which can be the same or different, are a hydrogen atom, a C_1 - C_4 alkyl group, or NR_7R_8 is a group selected from : i) guanidine optionally substituted with 1 or 2 C_1 - C_4 alkyl groups, cyclohexyl, ii) a 5-7 membered nitrogen heterocycle optionally containing another heteroatom selected from O, N, S;


- Y_1 is selected from the group consisting of $-NR_7R_8$ and from the residues




- R₉ is selected from the group consisting of hydrogen, - (CH₂)_q-L, wherein L is selected from the group -NR₅R₆, amidine optionally substituted with 1 or 2 C₁-C₄ alkyl groups, guanidine optionally substituted with 1 or 2 C₁-C₄ alkyl groups; and the other substituents are as previously defined in claim 2.

6. (currently amended) Compounds as claimed in claim 2, of general formula (I), containing at least one tetraalkyl ammonium, in which:


- R_1 is a hydrogen atom or methyl;
- R_2 and R_3 , which can be the same or different, are selected from methyl or ethyl, or R_2 and R_3 , together with the carbon atom which they are linked to, form a cyclic aliphatic group having 3 to 7 carbon atoms;
- R_4 and R_5 , which can be the same or different, are a hydrogen or a methyl;
- X is a chlorine atom;
- B is selected from the group consisting of NR_6Y , and from the residues:



- Y is selected from: Y , COY , $(CH_2)_pY_1$, $NR_6(CH_2)_qY_1$ and from the residues:



- T is selected from the group $-NR_7R_8$, $-NR_{14}R_{18}R_{19}$, $-OR_6$;
- Y_1 is selected from the group consisting of $-NR_7R_8$, $-NR_7R_8R_{14}$ or from the following residues:



and the other substituents are as previously defined in claim 2.

7. (currently amended) Compounds of general formula (I), as claimed in ~~claims 1 to 6~~ claim 1, which are:

- N-[2-[4-(2-(S)-amino-6-dimethylamino-hexanoyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-2,4-dichloro-3-(2-methyl-quinolin-8-yloxy-methyl)-benzensulfonamide trifluoroacetate;
- N-{2-[4-(6-guanidinohexyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-2,4-dichloro-3-(2-methyl-8-quinolinoxymethyl)benzenesulfonamido -2-methyl-propionamide tris trifluoroacetate;
- 4-{2-[2,4-Dichloro-3-(2-methyl-quinolin-8-yloxymethyl)-benzene-sulfonylamino]-2-methyl-propionyl}-piperazine-1-carboxamidine;
- N-[2-[4-(2-(S)-amino-5-guanidino-pentanoyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-2,4-dichloro-3-(2-methyl-8-quinolinoxymethyl)-benzenesulfonamide tris trifluoroacetate;
- N-{2-[4-(6-aminohexyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-2,4-dichloro-3-(2-methyl-8-quinolinoxymethyl)-benzenesulfonamide tris trifluoroacetate;
- N-{2-[4-(piperazin-2-yl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-2,4-dichloro-3-(2-methyl-8-quinolinoxymethyl)-benzenesulfonamide tris trifluoroacetate;
- N-{2-[4-(piperazin-1-ylacetyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-2,4-dichloro-3-(2-methyl-8-quinolinoxymethyl)-benzene-sulfonamide bis trifluoroacetate;
- N-{2-[4-2-(piperidin-4-yl-acetyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-2,4-dichloro-3-(2-methyl-8-quinolinoxymethyl)-benzene-sulfonamide bis trifluoroacetate;
- N-{2-[4-[N-(4-piperidyl)glycyl]-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-2,4-dichloro-3-(2-methyl-8-

- quinolinoxymethyl)-benzene-sulfonamide tris trifluoroacetate;
- N-{2-[4-(4-(2-aminoethyl)piperazin-1-yl)acetyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-2,4-dichloro-3-(2-methyl-8-quinolinoxymethyl)-benzenesulfonamide tetra trifluoroacetate;
 - N-{2-[4-(3-(R)-Amino-6-guanidino-hexanoyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-2,4-dichloro-3-(2-methyl-8-quinolinoxymethyl)-benzenesulfonamide tris trifluoroacetate;
 - N-{2-[4-(3-(S)-amino-6-dimethylamino-hexanoyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-2,4-dichloro-3-(2-methyl-8-quinolinoxymethyl)-benzenesulfonamide tris trifluoroacetate;
 - N-{2-[4-(3-(S)-amino-7-dimethylamino-heptanoyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-2,4-dichloro-3-(2-methyl-8-quinolinoxymethyl)-benzenesulfonamide tris trifluoroacetate;
 - N-(3-Amino-propyl)-4-{2-[2,4-dichloro-3-(2-methyl-quinolin-8-yloxy-methyl)-benzenesulfonylamino]-2-methyl-propionyl}-piperazine-1-carboxamidine tris trifluoroacetate;
 - N-[2-[4-(2-(S)-amino-5-dimethylamino-pentanoyl))-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-2,4-dichloro-3-(2-methyl-8-quinolinoxy-methyl)-benzenesulfonamide tris trifluoroacetate;
 - (S)-N-{2-[1'-(2-Amino-5-guanidino-pentanoyl)-[4,4']bipiperidinyl-1-yl]-1,1-dimethyl-2-oxo-ethyl}-2,4-dichloro-3-(2-methyl-quinolin-8-yloxymethyl)-benzenesulfonamide;
 - 2,4-Dichloro-N-(2-{4-[2-(3,5-dimethyl-piperazin-1-yl)-ethyl]-3,5-dimethyl-piperazin-1-yl}-1,1-dimethyl-2-oxo-ethyl)-3-(2-methyl-4a,8a-dihydro-quinolin-8-yloxymethyl)-benzenesulfonamide;

- N-(2-{4-[4-(2-(S)Amino-5-guanidino-pentanoyl)-piperazin-1-yl]-piperidin-1-yl}-1,1-dimethyl-2-oxo-ethyl)-2,4-dichloro-3-(2-methyl-quinolin-8-yloxymethyl)-benzenesulfonamide;
- 2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfinic acid [1-(4-piperazin-1-yl-piperidine-1-carbonyl)-cyclopentyl]-amide;
- 2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfinic acid (1-{4-[4-(2-S-amino-6-guanidino-hexanoyl)-piperazin-1-yl]-piperidine-1-carbonyl}-cyclopentyl)-amide;
- 2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfinic acid (1-{4-[4-(2-S-amino-5-guanidino-pentanoyl)-piperazin-1-yl]-piperidine-1-carbonyl}-cyclopentyl)-amide;
- 2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfinic acid [1-(4-piperidin-4-yl-piperazine-1-carbonyl)-cyclopentyl]-amide;
- 2,4-Dichloro-3-(2-methyl-quinolin-8-yloxymethyl)-benzenesulfinic acid {2-[4-(2-guanidino-ethyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-amide;
- 2,4-Dichloro-3-(2-methyl-quinolin-8-yloxymethyl)-benzenesulfinic acid (2-{4-[2-S-amino-5-(N',N''-diethyl-guanidino)-pentanoyl]-piperazin-1-yl}-1,1-dimethyl-2-oxo-ethyl)-amide;
- 2,4-Dichloro-3-(2-methyl-quinolin-8-yloxymethyl)-benzenesulfinic acid (2-{4-[2-R-amino-5-(N',N''-diethyl-guanidino)-pentanoyl]-piperazin-1-yl}-1,1-dimethyl-2-oxo-ethyl)-amide;
- (2S)-N-(1-{4-[2-Amino-6-(N',N''-diethyl-guanidino)-hexanoyl]-piperazine-1-carbonyl}-cyclopentyl)-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide;

- N- (1- {4- [2- (S) Amino-6- (N', N'' -diethyl-guanidino) - pentanoyl] -piperazine-1-carbonyl} -cyclopentyl) -2,4-dichloro-3- (2,4-dimethyl-quinolin-8-yloxymethyl) - benzenesulfonamide;
- N- [2- [4- (2- (S) -Amino-6-dimethylamino-hexanoyl) -piperazin-1-yl] -1,1-dimethyl-2-oxo-ethyl] -2,4-dichloro-3- (2,4-dimethyl-quinolin-8-yloxymethyl) -benzenesulfonamide;
- N- [2- [4- (3- (S) -Amino-6-dimethylamino-hexanoyl) -piperazin-1-yl] -1,1-dimethyl-2-oxo-ethyl] -2,4-dichloro-3- (2,4-dimethyl-quinolin-8-yloxymethyl) -benzenesulfonamide;
- N- [2- [4- (3- (S) -Amino-6-dimethylamino-heptanoyl) - piperazin-1-yl] -1,1-dimethyl-2-oxo-ethyl] -2,4-dichloro-3- (2,4-dimethyl-quinolin-8-yloxy methyl) - benzenesulfonamide;
- N- [2- [4- (2- (S) -Amino-5-guanidino-pentanoyl) -piperazin-1-yl] -1,1-dimethyl-2-oxo-ethyl] -2,4-dichloro-3- (2,4-dimethyl-quinolin-8-yloxymethyl) -benzenesulfonamide;
- N- [2- [4- (2- (S) -Amino-6-guanidino-hexanoyl) -piperazin-1-yl] -1,1-dimethyl-2-oxo-ethyl] -2,4-dichloro-3- (2,4-dimethyl-quinolin-8-yloxymethyl) -benzenesulfonamide;
- N- [2- [4- (2- (S) -Amino-5-dimethylamino-pentanoyl)) - piperazin-1-yl] -1,1-dimethyl-2-oxo-ethyl] -2,4-dichloro-3- (2,4-dimethyl-quinolin-8-yloxymethyl) -benzenesulfonamide;
- N- [2- [4- (2- (R) -Amino-5-guanidino-pentanoyl) -piperazin-1-yl] -1,1-dimethyl-2-oxo-ethyl] -2,4-dichloro-3- (2-methyl-quinolin-8-yloxy-methyl) -benzenesulfonamide;
- N- [2- [4- (3- (S) -Amino-6-guanidino-hexanoyl) -piperazin-1-yl] -1,1-dimethyl-2-oxo-ethyl] -2,4-dichloro-3- (2-methyl-quinolin-8-yloxy-methyl) -benzenesulfonamide;
- N- [2- [4- (3- (S) -Amino-7-guanidino-heptanoyl) -piperazin-1-yl] -1,1-dimethyl-2-oxo-ethyl] -2,4-dichloro-3- (2-methyl-quinolin-8-yloxy-methyl) -benzenesulfonamide;

- N-{2-[4-(4-2(Guanidino)ethyl)piperazin-1ylacetyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-2,4-dichloro-3-(2-methyl-quinolin-8-yloxymethyl)-benzenesulfonamide;
- N-[1-[4-(2-(S)-Amino-5-guanidino-pentanoyl)-piperazine-1-carbonyl]-cyclopentyl]-2,4-dichloro-3-(2-methyl-quinolin-8-yloxymethyl)-benzenesulfonamide tris trifluoroacetate;
- N-[1-[4-(2-(S)-Amino-6-guanidino-hexanoyl)-piperazine-1-carbonyl]-cyclopentyl]-2,4-dichloro-3-(2-methyl-quinolin-8-yloxymethyl)-benzenesulfonamide tris trifluoroacetate;
- N-[1-[4-(2-(S)-Amino-6-dimethylamino-hexanoyl)-piperazin-1-yl]-cyclopentyl]-2,4-dichloro-3-(2-methyl-quinolin-8-yloxymethyl)-benzenesulfonamide tris trifluoroacetate;
- N-[1-[4-(2-(S)-Amino-6-guanidino-hexanoyl)-piperazine-1-carbonyl]-cyclopentyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tris trifluoroacetate;
- N-[1-[4-(2-(S)-Amino-6-dimethylamino-hexanoyl)-piperazin-1-yl]-cyclopentyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tris trifluoroacetate;
- (R)-N-[4-(2-(S)-Amino-6-guanidino-hexanoyl)-piperazine-1-carbonyl]-1-methyl-propyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tris trifluoroacetate;
- (R)-N-[1-[4-(2-(S)-Amino-6-dimethylamino-hexanoyl)-piperazine-1-carbonyl]-1-methyl-propyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tris trifluoroacetate;
- N-{2-[4-(4-2(Guanidino)ethyl)piperazin-1ylacetyl)-piperazin-1-carbonyl]-cyclopentyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tetra trifluoroacetate;
- N-[1-[4-(2-(R)-Amino-6-amino-hexanoyl)-piperazine-1-carbonyl]-cyclopentyl]-2,4-dichloro-3-(2,4-dimethyl-

- quinolin-8-yloxymethyl)-benzenesulfonamide tris trifluoroacetate;
- N-[1-[4-(2-(R)-Amino-6-guanidino-hexanoyl)-piperazine-1-carbonyl]-cyclopentyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tris trifluoroacetate;
 - N-[2-[4-(3-(S)-Amino-6-guanidino-hexanoyl)-piperazin-1-carbonyl]-cyclopentyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tris trifluoroacetate;
 - N-[2-[4-(3-(S)-Amino-6-dimethylamino-hexanoyl)-piperazin-1-carbonyl]-cyclopentyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tris trifluoroacetate;
 - N-[1-[4-(6-Guanidino-hexanoyl)-piperazine-1-carbonyl]-cyclopentyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzene-sulfonamide bis trifluoroacetate;
 - N-[2-[4-(2-(S)-Amino-6-amino-hexanoyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-2,4-dichloro-3-(2-methyl-quinolin-8-yloxymethyl)-benzenesulfonamide tris trifluoroacetate;
 - N-[2-[4-(2-(S)-Guanidino-6-guanidino-hexanoyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-2,4-dichloro-3-(2-methyl-quinolin-8-yloxy-methyl)-benzenesulfonamide tris trifluoroacetate;
 - (R)-N-[4-(3-(S)-Amino-6-guanidino-hexanoyl)-piperazine-1-carbonyl]-1-methyl-propyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxy-methyl)-benzenesulfonamide tris trifluoroacetate;
 - (R)-N-{2-[4-(4-2(Guanidino)ethyl)piperazin-1-ylacetyl)-piperazin-1-carbonyl]-1-methyl-propyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tetra trifluoroacetate;


- (R) -N- [4- (3- (S) -Amino-6-amino-hexanoyl) -piperazine-1-carbonyl] -1-methyl-propyl] -2,4-dichloro-3- (2,4-dimethyl-quinolin-8-yloxymethyl) -benzenesulfonamide tris trifluoroacetate;
- (R) -N- [4- (3- (S) -Guanidino-6-guanidino-hexanoyl) -piperazine-1-carbonyl] -1-methyl-propyl] -2,4-dichloro-3- (2,4-dimethyl-quinolin-8-yloxymethyl) -benzenesulfonamide tris trifluoroacetate;
- (R) -N- [4- (3- (S) -Amino-6-dimethylamino-hexanoyl) -piperazine-1-carbonyl] -1-methyl-propyl] -2,4-dichloro-3- (2,4-dimethyl-quinolin-8-yloxymethyl) -benzenesulfonamide tris trifluoroacetate;
- (S) -N- [4- (2- (S) -Amino-6-guanidino-hexanoyl) -piperazine-1-carbonyl] -1-methyl-propyl] -2,4-dichloro-3- (2,4-dimethyl-quinolin-8-yloxy-methyl) -benzenesulfonamide tris trifluoroacetate;
- (S) -N- [4- (3- (S) -Amino-6-guanidino-hexanoyl) -piperazine-1-carbonyl] -1-methyl-propyl] -2,4-dichloro-3- (2,4-dimethyl-quinolin-8-yloxy-methyl) -benzenesulfonamide tris trifluoroacetate;
- 2,4-Dichloro-N- {1- [4- (3 (S) , 6-diamino-hexanoyl) -piperazine-1-carbonyl] -cyclopentyl} -3- (2,4-dimethyl-quinolin-8-yloxymethyl) -benzenesulfonamide tris trifluoroacetate;
- 2,4-Dichloro-N- {1- [4- (3 (S) , 6-diguanidino-hexanoyl) -piperazine-1-carbonyl] -cyclopentyl} -3- (2,4-dimethyl-quinolin-8-yloxymethyl) -benzenesulfonamide tris trifluoroacetate;
- N- (1- {4- [3- (S) , 6-Bis- (N' , N' '-dicyclohexyl-guanidino) -hexanoyl] -piperazine-1-carbonyl} -cyclopentyl) -2,4-dichloro-3- (2,4-dimethyl-quinolin-8-yloxymethyl) -benzensulfonamide tris trifluoroacetate;
- N- {1- [4- (2- (S) Amino-3-piperidin-4-yl-propionyl) -piperazine-1-carbonyl] -cyclopentyl} -2,4-dichloro-3- (2,4-

- dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tris trifluoroacetate;
- N-{1-[4-(2-Trimethylammonium-acetyl)-piperazine-1-carbonyl]-cyclopentyl}-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide bis trifluoroacetate;
 - N-{1-[4-(4-Trimethylammonium-butanoyl)-piperazine-1-carbonyl]-cyclopentyl}-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide bis trifluoroacetate;
 - N-{1-[4-(3(R)-Hydroxy-4-trimethylammonium-butanoyl)-piperazine-1-carbonyl]-cyclopentyl}-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxy-methyl)-benzenesulfonamide bis trifluoroacetate;
 - N-[1-[4-(2-(S)-Dimethylamino-6-dimethylamino-hexanoyl)-piperazin-1-yl]-cyclopentyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxy-methyl)-benzenesulfonamide tris trifluoroacetate;
 - {5-[(1-{1-[2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzensulfonylamino]-cyclopentanecarbonyl}-piperidin-4-ylmethyl)-dimethyl-ammonium]pentyl}-trimethyl-ammonium tris trifluoroacetate;
 - {5-[(1-{1-[2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzensulfonylamino]-cyclopentanecarbonyl}-piperidine-4-carbonyl)-amino]-pentyl}-trimethyl-ammonium bis trifluoroacetate;
 - N-[1-[4-(2-(S)-Trimethylammonium-6-trimethylammonium-hexanoyl)-piperazin-1-yl]-cyclopentyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tris trifluoroacetate;
 - N-[1-[4-(2-(R)-Trimethylammonium-6-trimethylammonium-hexanoyl)-piperazin-1-yl]-cyclopentyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tris trifluoroacetate;

- N-[1-[4-(2-(S)-Trimethylammonium-6-amino-hexanoyl)-piperazin-1-yl]-cyclopentyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tris trifluoroacetate;
- N-{1-[4-(6-Trimethylammonium-hexanoyl)-piperazine-1-carbonyl]-cyclopentyl}-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide bis trifluoroacetate;
- N-(6-Amino-hexyl)-4-{2-[2,4-dichloro-3-(2-methyl-quinolin-8-yloxy-methyl)-benzenesulfonylamino]-2-methyl-propionyl}-piperazine-1-carboxamidine;
- N-[2-(3-Amino-propylamino)-ethyl]-4-{2-[2,4-dichloro-3-(2-methyl-quinolin-8-yloxymethyl)-benzenesulfonylamino]-2-methyl-propionyl}-piperazine-1-carboxamidine;
- N-(3-Amino-propyl)-4-{2-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonylamino]-2-methyl-propionyl}-piperazine-1-carboxamidine bis trifluoroacetate;
- N-(6-Amino-hexyl)-4-{1-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonylamino]-cyclopentanecarbonyl}-piperazine-1-carboxamidine bis trifluoroacetate;
- N-[2-(3-Amino-propylamino)-ethyl]-4-{1-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonylamino]-cyclopentanecarbonyl}-piperazine-1-carboxamidine bis trifluoroacetate:
- N-[2-(4-{1-[2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonylamino]-cyclopentanecarbonyl}-piperazin-1-yl)-ethyl]-4-methyl-piperazine-1-carboxamidine bis trifluoroacetate;
- 2,4-Dichloro-N-{1-[4-(2(R),6-diamino-hexyl)-piperazine-1-carbonyl]-cyclopentyl}-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzene-sulfonamide tetra trifluoroacetate;


- 2,4-Dichloro-N-{1-[4-(2(R),6-diguanidino-hexyl)-piperazine-1-carbonyl]-cyclopentyl}-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tetrahydrochloride
- 2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-N-{1-[4-(2-piperazin-1-yl-ethyl)-piperazine-1-carbonyl]-cyclopentyl}-benzenesulfonamide tetra trifluoroacetate;
- 2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-N-{1-[4-(2-piperidin-4-yl-ethyl)-piperazine-1-carbonyl]-cyclopentyl}-benzene-sulfonamide;
- {3-[(4-{1-[2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonylamino]-cyclopentanecarbonyl}-piperazine-1-carboximido-yl)-amino]propyl}-trimethyl-ammonium tris trifluoroacetate;
- 4-{1-[2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzene-sulfonylamino]-cyclopentanecarbonyl}-N-(3-dimethylamino-propyl)-piperazine-1-carboxamide tris trifluoroacetate;
- N-(1-{4-[(5-Amino-pentylamino)-methyl]-piperidine-1-carbonyl}-cyclopentyl)-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tris trifluoroacetate;
- N-{1-[4-(4-Amino-piperidin-1-ylmethyl)-piperidine-1-carbonyl]-cyclopentyl}-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tris trifluoroacetate;
- 2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-N-(1-{4-[(5-methylamino-pentylamino)-methyl]-piperidine-1-carbonyl}-cyclopentyl)-benzenesulfonamide tris trifluoroacetate;
- Amino-6-(4-{1-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonylamino]-cyclopentanecarbonyl}-piperazin-1-yl)-6-oxo-hexyl]-trimethyl-ammonium bis trifluoroacetate.

8.(original) Intermediates of general formula (6) or (7)



in which R_1 can be H or methyl, R_2 and R_3 can be independently methyl, ethyl or, together with the carbon atom which they are linked to, form a cyclopentyl group, and R_{14} is methyl or t-butyl.

9.(original) Intermediates of general formula (1)



in which R_1 can be H or methyl, R_2 and R_3 can be independently methyl, ethyl or, together with the carbon atom which they are linked to, form a cyclopentyl group.

10.(currently amended) Pharmaceutical compositions containing as active ingredient a compound as claimed in ~~any~~

~~one of claims 1 to 7~~ claim 1, together with pharmaceutically acceptable excipients, for the treatment of disorders in which the use of a bradykinin antagonist is needed.

11.(currently amended) The use of a compound as claimed in ~~any one of claims 1 to 7~~ claim 1, for the preparation of pharmaceutical compositions for the treatment of disorders in which the use of a bradykinin antagonist is needed.

12.(original) The use of a compound as claimed in claim 11 for the preparation of pharmaceutical compositions for the treatment of inflammatory, allergic and autoimmune disorders.

13.(original) The use of a compound as claimed in claim 11 for the preparation of pharmaceutical compositions for the treatment of disorders such as asthma and chronic bronchitis, allergic, vasomotor and viral rhinitis, obstructive pulmonary disease (COPD), rheumatoid arthritis, chronic inflammatory diseases of the bowel (Crohn's disease and ulcerative colitis), glomerulonephritis, psoriasis, rash, acute and chronic cystitis, hepatic cirrhosis, glomerulopathies and pulmonary fibrosis, arteriosclerosis, both acute and chronic pain, septic, allergic and post-traumatic shocks, hepatic cirrhosis by hepatorenal syndrome, hypotension, alopecia, or as anticancer and antiangiogenetics.